Table 3.
Summary of subjects with an overall response of PR or better
| Subject (Age/Sex) | Tumor Type | Best Response | Time to Best Response (Months) | Duration of SMK Therapy (Months) | ECOG Score* (Baseline / End of Cycle 1) | EORTC Global Health Status Score# (Baseline / End of Cycle 1) |
|---|---|---|---|---|---|---|
| 70/Female | Breast | CR | 1.5 | 4.1 | 2/1 | 5/7 |
| 50/Female | Breast | CR | 3.3 | 40.9 | 1/0 | 3/7 |
| 51/Female | Breast | CR | 3.2 | 14.8 | 2/1 | 3/6 |
| 57/Male | Appendix | CR | 5.6 | 4.7 | 1/0 | 5/7 |
| 40/Female | Breast | PR | 1.4 | 7.7 | 3/1 | 4/6 |
| 54/Female | Breast | PR | 1.4 | 3.3 | 2/1 | 7/6 |
| 58/Female | Lung | PR | 4.1 | 14.3 | 2/1 | 4/5 |
| 58/Male | Pancreas | PR | 3.4 | 3.4 | 2/1 | 4/5 |
| 48/Female | Breast | PR | 1.5 | 3.1 | 1/0 | 4/6 |
| 33/Female | Thyroid | PR | 15.5 | 12.9 | 1/0 | 3/7 |
*A reduction in ECOG score indicates improvement. #An increase in EORTC global health status score indicates an improvement